Therapies Beyond the Front Line for SCLC

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Anne Chiang, MD, PhD

Key Takeaways

Tarlatamab is a newly approved therapy, marking progress beyond first-line treatments for SCLC.
Researchers are exploring novel agents and combination therapies to enhance patient outcomes in SCLC.
Exciting clinical trials focus on targeting molecular pathways and boosting immune response in SCLC.
Future SCLC management may involve personalized strategies, integrating emerging therapies and precision medicine advancements.

Panelists discuss how treatment options for small cell lung cancer (SCLC) extend beyond first-line therapies and the recently approved tarlatamab, exploring existing treatments in the second-line and beyond while also highlighting promising ongoing clinical trials and emerging therapies that show potential for improving outcomes in SCLC patients.

EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC

EP: 2.Established Multidisciplinary Therapies for SCLC

EP: 3.Immunotherapies for Extensive-Stage SCLC

EP: 4.Introducing Bispecifics for Extensive-Stage SCLC

EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC

EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC

EP: 7.Payer and Patient Education Considerations for SCLC

EP: 8.Biomarker Discovery and Exploration for SCLC

EP: 9.Key Takeaways on Recent Advances in SCLC

Now Viewing

EP: 10.Therapies Beyond the Front Line for SCLC

EP: 11.Timing and Urgency Considerations in SCLC

We’ve discussed first-line therapies and a newly approved therapy tarlatamab.

Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about?
What are some of the therapies being researched for small cell lung cancer (SCLC) that you are excited about?

How do you see the management of SCLC evolving in the future?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!